Comments*

 
  • Drug Development

  • Events 

    Tuesday, December 9, 2014 | 8:00 AM - 5:00 PM

    Diabetic Kidney Disease: Drug Discovery and Clinical Development Challenges

    Speakers: Matthew D. Breyer (Eli Lilly and Company), Frank C. Brosius (University of Michigan Medical School), Benjamin D. Humphreys (Brigham and Women's Hospital), Matthias Meier (F. Hoffmann-La Roche Ltd), Shahnaz Shahinfar (S. Shahinfar Consulting, Inc. and The Children's Hospital of Philadelphia), Katalin Susztak (University of Pennsylvania), Aliza Thompson (Food and Drug Administration)

    Identifying and prosecuting drug targets is challenging due to a poor understanding of pathogenesis and few biomarkers. This symposium identifies targets for preventive or therapeutic interventions and discusses challenges in clinical development.

    Tuesday, January 27, 2015 | 8:30 AM - 4:30 PM

    Cytokine-Based Immunotherapies

    Keynote Speaker: James W. Mier (Beth Israel Deaconess Medical Center/ Harvard Medical School, Boston, MA)
    Speakers: Stephen D. Gillies (Provenance Biopharmaceuticals, Carlisle, MA), Dario Neri (Philogen, Zurich, Switzerland), Jerome Ritz (Harvard Medical School), Gilles Uzé (Université Montpellier II, Montpellier, France), K. Dane Wittrup (Massachusetts Institute of Technology, Cambridge, MA)

    Systemic toxicity currently prevents exploiting the potential of many cytokines to treat cancer, viral infections, inflammatory and autoimmune conditions. Targeted delivery of immune-stimulatory or immune-regulatory cytokines offers much promise.

    Tuesday, February 24, 2015 | 8:30 AM - 4:30 PM

    Harnessing the Potential of Genome Editing for Drug Discovery: Translational Frontiers of in vitro and in vivo Applications

    Speakers: James Inglese (National Center for Advancing Translational Sciences), Yi Yang (Novartis Institutes for Biomedical Research)

    The emergence of genome editing technologies such as TALEN and CRISPR/Cas9 are revolutionizing our ability to rapidly engineer mammalian systems. This symposium explores the frontiers of genome editing and potential to aid therapeutic development.

  • Past Events

    Saturday, November 15, 2014 | 11:00 AM - 4:00 PM

    Risky Business – A Pharmaceutical Industry Strategy Workshop

    Moderator: Jan-Philipp Kruse (Catenion)

    This course gives professionals from inside and outside the pharmaceutical industry—including students and postdocs—a much better understanding of how the R&D and business development and licensing processes operate.

    Tuesday, October 28, 2014 | 8:30 AM - 5:00 PM

    Pharmacologic Resolution of Inflammation as a Novel Therapeutic Approach

    Speaker: Michael S. Conte (University of California-San Francisco), Milan Fiala (David Geffen School of Medicine at UCLA), Gabrielle Fredman (Columbia University), Bruce Levy (Harvard University, Brigham and Women's Hospital), Dipak Panigrahy (Beth Israel Deaconess Medical Center, Harvard Medical School), Mauro Perretti (Queen Mary University of London), Charles N. Serhan (Brigham & Women's Hospital, Harvard Medical School), Patricia J. Sime (University of Rochester School of Medicine), Rudolph E. Tanzi (Massachusetts General Hospital)

    Uncontrolled, chronic inflammation plays a key role in the progression of many diseases, and elucidation of biochemical pathways provides novel targets. This symposium reviews discoveries, approaches and opportunities for treatment and prevention.

    Friday, October 10, 2014 | 8:00 AM - 3:15 PM

    New Frontiers in the Neurobiology of Mental Illness

    Sold Out
    Keynote Speaker: The Honorable Patrick J. Kennedy
    Former United States Representative, Rhode Island; One Mind for Research; Kennedy Forum

    This conference will explore the translation of recent breakthroughs in neuroscience into therapies for the more than twenty-five percent of Americans suffering from mental illnesses such as schizophrenia, depression, fear and anxiety disorders, autism, and other psychiatric disorders. A keynote lecture by The Honorable Patrick J Kennedy will address strategies to simultaneously abolish the stigma surrounding mental illness in order to fully realize the potential of these new treatments to improve mental health.

    Thursday, October 9, 2014 | 8:00 AM - 4:00 PM

    Targeting Key Vulnerabilities in Pancreatic Cancer

    Keynote Speakers: Neesha Dhani (Princess Margaret Hospital, Toronto), Steven D. Leach (Memorial Sloan Kettering Cancer Center)
    Speakers: Gregory Beatty (University of Pennsylvania Perelman School of Medicine), Neesha C. Dhani (Division of Medical Oncology & Hematology, University Health Network, Princess Margaret Cancer Centre/Ontario Cancer Institute), Mikala Egeblad (Cold Spring Harbor Laboratory), Douglas T. Fearon (Weill Cornell Medical College and Cold Spring Harbor Laboratory), Elda Grabocka (Department of Biochemistry and Molecular Pharmacology, NYU Langone School of Medicine), Costas A. Lyssiotis (Weill Cornell Medical College ), George Miller (NYU Langone Medical Center), Michael Ports (Gilead Sciences), Curtis B. Thompson (Halozyme Therapeutics, Inc)

    Pancreatic cancer patients currently have limited therapeutic options. This symposium explores breakthroughs in the pathogenesis and progression of pancreatic cancer, and efforts to exploit key vulnerabilities for novel therapeutic interventions.

  • Publications 

    eBriefing

    Click Chemistry in Biology and Medicine

    Organizers: Peng Wu (Albert Einstein College of Medicine) and Jennifer Henry (formerly at The New York Academy of Sciences)
    Keynote Speakers: Jim Paulson (Scripps Research Institute) and K. Barry Sharpless (Scripps Research Institute)

    This eBriefing explores recent developments in the search for click reactions with applications in disease diagnosis and therapy.

    Annals

    Pharmaceutical Science to Improve the Human Condition: Winners and Finalists for the Prix Galien USA Awards 2013

    Edited by Annals of the New York Academy of Sciences editorial staff

    This Annals volume presents scientific achievements by winners and finalists of the 2013 Prix Galien USA, honoring excellence in pharmaceutical science.

    Volume 1329

    eBriefing

    Elucidating GPCR Functional Selectivity for Drug Development

    Organizers: John A. Allen (Pfizer), Mercedes Beyna (Pfizer), Bryan L. Roth (University of North Carolina School of Medicine), and Jennifer Henry (formerly at The New York Academy of Sciences)

    This eBriefing looks at how to exploit biased ligand signaling at GPCRs to improve therapeutics for cardiovascular and CNS disorders.

    Annals

    Addiction Reviews

    Edited by George R. Uhl (National Institutes of Health, Baltimore, Maryland)

    The sixth installment of this annual series explores molecular and translational/therapeutic aspects of addiction.

    Volume 1327

  • Podcasts

    Podcast
    April 2, 2010

    More than a Yogurt Cup

    Delve into the world of prebiotic and probiotic science. We talk to three people in the field and learn why keeping the good microbes in our bodies happy means a lot for health.

    Download (14 MB, 00:21:21)
    Podcast
    January 15, 2010

    Feeling the Light

    Researchers at Harvard have discovered why the headaches of some migraine sufferers worsen when the person is exposed to light. Rami Burstein, the study's senior author, explains what's happening in the brain, and how they made the breakthrough.

    Download (15 MB, 00:22:48)
    Podcast
    December 18, 2009

    No Small Matter

    We sit down with science photographer Felice Frankel and nanotechnology pioneer and Harvard chemist George Whitesides to hear about their new book on nanoscience, No Small Matter.

    Download (11 MB, 00:18:04)
    Podcast
    October 16, 2009

    Looking for the Key in P53

    Visit the lab of Hunter College's Jill Bargonetti, a biologist researching cancer. Her team studies P53, a natural tumor-suppressor protein found in our bodies with a Dr. Jekyll and Mr. Hyde personality.

    Download (11 MB, 00:17:20)
  • Webinar Archives

    Webinar Archive
    February 23, 2010

    Metabotropic Glutamate Receptors: Translation from Discovery to Clinical Trials

    Researchers met to discuss advances in basic and translational research on metabotropic glutamate receptors, which are promising targets in drug discovery for CNS diseases and other illnesses.

    Webinar Archive
    October 27, 2009

    Is Alzheimer's Disease Type 3 Diabetes?

    What is the connection between dysregulated neuronal insulin signaling and Alzheimer's disease? In a recent Academy webinar, some researchers argued that the neurodegenerative disease should be considered a type of diabetes.

    Webinar Archive
    April 28, 2009

    Protein Kinases: Structure-Guided Drug Discovery

    Protein kinases play a key role in almost every major pathway in eukaryotic cells. Structural approaches, including a new method called fragment-based drug design, are identifying potential targets against diseases including cancer.

  • Translational Medicine Initiative

    Macy FoundationThe Translational Medicine Initiative represents a three-year partnership between the New York Academy of Sciences and the Josiah Macy, Jr. Foundation to support the translation of basic science research into clinical applications.

    Learn more at www.nyas.org/TransMed.